# NextCure (NXTC) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/NXTC
## Company Profile
- Ticker: NXTC
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 8.17 USD
- Market cap: 12281126.4 USD
- Last updated: 2026-08-12
## Business Overview
### Oncology Drug Development
NextCure develops novel therapies for cancer, with a pipeline that includes antibody-drug conjugates and immune-modulating approaches.
### SIM0505
SIM0505 is an antibody-drug conjugate targeting cadherin-6 and carrying a topoisomerase-1 inhibitor payload. It is being evaluated in tumors with elevated CDH6 expression, including platinum-resistant ovarian cancer.
### LNCB74
LNCB74 is a separate Phase 1 oncology candidate undergoing dose escalation, providing NextCure with a second clinical-stage program.
## Why The Stock Is Moving

As of Aug 12, 2026, NXTC closed up 21.4% at $8.17. No new same-company headline was identified in the current news window.

## Future Catalysts

- Phase 1 dose-escalation data for SIM0505 at ASCO 2026.
- Phase 1 dose-escalation update for LNCB74 in the second half of 2026.

## Recent News
- 2026-08-06 20:01 EST — [NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/NXTC/nextcure-provides-business-update-and-reports-second-quarter-2026-financial-resu-b8c0c9e3) — Source: NextCure
- 2026-07-14 10:00 EST — [NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy](https://biopharmsignal.com/news/NXTC/nextcure-and-avere-therapeutics-announce-merger-to-advance-once-weekly-oral-il-2-9774b133) — Source: NextCure
- 2026-06-04 12:00 EST — [NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers](https://biopharmsignal.com/news/NXTC/nxtc-announces-replay-available-for-virtual-kol-event-discussing-asco-2026-dose--a8660fb2) — Source: NextCure
- 2026-06-01 12:00 EST — [NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026](https://biopharmsignal.com/news/NXTC/nextcure-presents-positive-sim0505-phase-1-dose-escalation-data-in-patients-with-fb481c8c) — Source: NextCure
- 2026-05-07 20:05 EST — [NextCure Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/NXTC/nextcure-provides-business-update-and-reports-first-quarter-2026-financial-resul-833f438a) — Source: NextCure